Skip to main content
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. logo

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300357 ISIN · CNE100001R58 LEI · 3003000DMXTOIP2M8505 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,112 across all filing types
Latest filing 2026-05-22 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300357

About Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

https://www.wolwobiotech.com

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and commercialization of allergy diagnostic and therapeutic products. The company focuses on allergen immunotherapy (AIT), particularly sublingual immunotherapy (SLIT) solutions. Its flagship products include standardized allergen extracts, such as Dermatophagoides farinae drops, used for the treatment of allergic rhinitis and allergic asthma. Wolwo Bio provides a comprehensive range of diagnostic tools for identifying specific allergens and offers targeted treatment options to modify the underlying cause of allergic diseases. The company maintains a strong emphasis on biotechnological innovation and clinical research to improve patient outcomes in the field of respiratory and dermatological allergies.

Recent filings

Filing Released Lang Actions
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a formal announcement of the 2025 annual shareholders’ meeting resolutions, detailing the voting results (numbers of shares for, against, abstained, percentages) for each proposal. It is not the underlying annual report or financial statements, nor an officer certification. It specifically reports the outcomes of shareholder votes, matching the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-05-22 Chinese
关于浙江我武生物科技股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 78% confidence The document is a legal opinion letter from a law firm concerning the procedures and validity of the 2025 annual general meeting of Zhejiang Wuwu Biotechnology Co., Ltd. It details the meeting convening, voting procedures, and includes the full tabulation of shareholder voting results. This aligns with the definition of “Declaration of Voting Results & Voting Rights Announcements (DVA)” which covers official results from shareholder votes at an AGM.
2026-05-22 Chinese
独立董事2025年度述职报告-徐国良
Board/Management Information Classification · 70% confidence The document is an independent director’s 2025 annual duty performance report, detailing board and committee attendance, duties performed, and governance oversight. It is not an earnings or financial report, nor a proxy solicitation or dividend notice. It relates specifically to board-level information about the director’s role and board changes (end of term and re-election of the board). This aligns with “Board/Management Information” (MANG).
2026-04-23 Chinese
关于“质量回报双提升”行动方案的进展公告
Regulatory Filings Classification · 78% confidence The document is a corporate “公告” providing a progress update on a previously announced “quality and return dual improvement” action plan, including operational metrics, R&D milestones, governance enhancements and investor‐return measures. It is not a standalone earnings release (ER), quarterly/interim report (IR), dividend notice (DIV), management change (MANG), or any of the other specific categories (e.g., M&A, share issue, call transcript). It is also not simply announcing the publication of an annual/interim report (RPA). As it does not neatly fit any specialized filing category, it falls under the fallback category of a general regulatory announcement. Thus, it is classified as Regulatory Filings (RNS).
2026-04-23 Chinese
关于会计估计变更的公告
Regulatory Filings Classification · 89% confidence The document is a formal corporate announcement regarding a change in accounting estimates (研发支出资本化会计估计变更) approved by the board of directors, describing the nature, rationale, implementation date, and impacts per Chinese accounting standards. It is not an annual or interim financial report, earnings release, proxy statement, or board membership change. It is also not just notifying publication of another report but contains substantive policy change details. Therefore, it falls under general regulatory filings for miscellaneous corporate disclosures.
2026-04-23 Chinese
关于召开2025年年度股东会的通知
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a formal notice convening the company’s 2025 Annual General Meeting (AGM) of shareholders, detailing the meeting time, location, agenda items (proposals), voting arrangements (including proxy instructions and voting forms), and attachments such as the proxy authorization form and meeting registration form. It is not the Annual Report itself but the materials sent to shareholders to provide information and solicit votes. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-23 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.